Cocrystal Pharma Announces $40 Million Bought Deal Offering of Common Stock
May 04, 2021 18:41 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., May 04, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma Reports 2020 Financial Results, Provides Business Update Including Antiviral Program Milestones
March 17, 2021 08:30 ET
|
Cocrystal Pharma, Inc.
Outlines 2021 product pipeline milestones for COVID-19, influenza A and norovirus antiviral programs Ends 2020 with cash exceeding $33 million and a clean capital structure BOTHELL, Wash., March...
Cocrystal Pharma Extends Drug Discovery Collaboration with HitGen and InterX
March 10, 2021 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash, March 10, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma to Present at the H.C. Wainwright Global Life Sciences Virtual Conference [UPDATED]
March 02, 2021 11:28 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., March 02, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma Presentation at the reimagine Health Research Symposium Features Overview of Platform Technology and Four Antiviral Case Studies
January 21, 2021 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma Announces Further Development of Influenza A/B Antiviral Compounds by Merck under Exclusive Worldwide License and Collaboration Agreement
January 19, 2021 08:00 ET
|
Cocrystal Pharma, Inc.
Program advances within the agreement’s initial two-year timeframe BOTHELL, Wash., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a...
Cocrystal to Present at the 3rd Annual reimagine Health Research Symposium
January 14, 2021 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma to Present at Virtual NobleCon17 Conference on January 19, 2021
January 12, 2021 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma to Present at the H.C. Wainwright 6th Annual Israel Conference
November 06, 2020 08:00 ET
|
Cocrystal Pharma, Inc.
– Live video webcast with the Cocrystal management team, on Thursday, November 12th at 12:00 PM EST – BOTHELL, WA, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP),...
Cocrystal Pharma Provides Update on Influenza A Program
October 19, 2020 08:05 ET
|
Cocrystal Pharma, Inc.
– New in vitro data demonstrating antiviral activity with lead compound CC-42344 against Xofluza (baloxavir)-resistant H1N1 strain – – Company continues to advance IND-enabling studies for...